Harmonization Fail: ICH Guideline Doesn’t Simplify Safety Reporting, Firms Say
Executive Summary
Crucially, the synchronization of landmark dates and reporting periods seems not to have been resolved by publication of the FDA/ICH document.
You may also be interested in...
Benefit-Risk Assessment Framework Pushes Into Post-Approval Arena
An industry/regulator working group will flesh out the processes involved in the eight-step framework and identify data that can be used at each step, in both the pre-market and post-market stage.
Post-Market Safety Updates Replaced By “Periodic Benefit-Risk Evaluation Reports”
Draft guidance from FDA would adopt the International Conference on Harmonization’s periodic benefit-risk evaluation reports, which will offer sponsors the opportunity to provide updates on benefit information along with safety signals to the regulatory authorities.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.